In this retrospective study, researchers sought to determine the survival impact of reductions in total cumulative dose and early vs late dose reductions of third-generation adjuvant chemotherapy regimens in patients with early-stage breast cancer.
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech)
Researchers examined the link between consuming different types of meat and the incidence of invasive breast cancer. We review their findings.
Findings from prospective cohort study of sisters or half-sisters of women diagnosed with breast cancer.
[Breast Cancer: Targets and Therapy] A series of semi-structured interviews with breast specialists revealed how surgeons’ own beliefs regarding patients’ ability to accept death influenced how they managed treatment decision making.
Time interval from diagnosis to surgery has largest impact on time from diagnosis to chemo initiation.
Emerging overall survival data show a benefit of this type of drug across a variety of patient subgroups.
Odds of TNBC diagnosis increased for black, Hispanic, and younger women.
[Cancer Management and Research] Despite the efficacy of radiotherapy, response to treatment can vary by breast cancer subtype and type of therapy. In this review, researchers summarize the prognostic differences and discuss potential reasons for them.
Biosimilars Mvasi and Kanjinti are now available in the United States.
